OppenheimerFunds Inc. acquired a new stake in shares of AnaptysBio Inc (NASDAQ:ANAB) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,059,381 shares of the biotechnology company’s stock, valued at approximately $106,701,000.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of AnaptysBio by 104.1% in the fourth quarter. BlackRock Inc. now owns 1,393,305 shares of the biotechnology company’s stock valued at $140,334,000 after acquiring an additional 710,574 shares during the period. Perceptive Advisors LLC raised its stake in shares of AnaptysBio by 3.2% in the third quarter. Perceptive Advisors LLC now owns 982,269 shares of the biotechnology company’s stock valued at $34,330,000 after acquiring an additional 30,000 shares during the period. Citadel Advisors LLC purchased a new stake in shares of AnaptysBio in the third quarter valued at $20,406,000. Vanguard Group Inc. raised its stake in shares of AnaptysBio by 22.6% in the second quarter. Vanguard Group Inc. now owns 206,031 shares of the biotechnology company’s stock valued at $4,931,000 after acquiring an additional 37,932 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of AnaptysBio by 210.2% in the third quarter. JPMorgan Chase & Co. now owns 183,319 shares of the biotechnology company’s stock valued at $6,363,000 after acquiring an additional 124,219 shares during the period. 95.56% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages have recently weighed in on ANAB. Wedbush reissued a “positive” rating and issued a $82.00 target price (up previously from $75.00) on shares of AnaptysBio in a research note on Tuesday, November 7th. Jefferies Group increased their target price on shares of AnaptysBio from $6.59 to $145.00 and gave the company a “buy” rating in a research note on Monday, February 19th. ValuEngine raised shares of AnaptysBio from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. SunTrust Banks increased their target price on shares of AnaptysBio from $115.00 to $162.00 and gave the company a “buy” rating in a research note on Thursday, February 15th. Finally, Zacks Investment Research raised shares of AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 target price on the stock in a research note on Friday, November 10th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $118.67.
AnaptysBio Inc (NASDAQ ANAB) opened at $123.12 on Friday. The company has a market cap of $2,980.00 and a PE ratio of -81.54. AnaptysBio Inc has a 12 month low of $18.15 and a 12 month high of $134.00. The company has a quick ratio of 10.77, a current ratio of 10.77 and a debt-to-equity ratio of 0.09.
ILLEGAL ACTIVITY WARNING: “OppenheimerFunds Inc. Acquires New Stake in AnaptysBio Inc (ANAB)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/24/oppenheimerfunds-inc-acquires-new-stake-in-anaptysbio-inc-anab.html.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.